Last 13 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -120.58 | — | — | — | — | 12.86 | — | 22.02 | — | 0.47 | — | — | — |
| — | — | — | — | — | +2661.8% | — | — | — | — | — | — | — | |
| P/S Ratio | 38.70 | 1891177.48 | 1639.52 | 883.28 | 235.69 | 237.02 | 474.15 | 258.50 | 234.54 | 152.35 | 616.52 | 88.48 | 50.04 |
| — | +797803.0% | +245.8% | +241.7% | +0.5% | +55.6% | -23.1% | +192.1% | +368.7% | +82.3% | — | — | — | |
| P/B Ratio | 4.05 | 3040.07 | 2.14 | 1.59 | 1.38 | 1.54 | 1.52 | 1.40 | 1.31 | 1.44 | 6.79 | 5.74 | 3.41 |
| — | +196745.0% | +41.0% | +13.6% | +4.8% | +7.2% | -77.6% | -75.6% | -61.5% | -63.9% | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | 0.16 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Roivant Sciences Ltd.'s operating margin was -16966.1% in Q3 2025, up 2526.7 pp QoQ and down 13923.5 pp YoY. The trailing four-quarter average of -13338.4% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 33.1% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.9% | 65.0% | 92.9% | 92.9% | 97.3% | 97.1% | 94.8% | 97.3% | 75.1% | 98.7% | 93.9% | 80.5% | 65.7% |
| — | -33.1% | -1.9% | -4.6% | +29.5% | -1.6% | +0.9% | +20.9% | +14.3% | +92.9% | — | — | — | |
| Operating Margin | -3453.3% | -16966.1% | -19492.9% | -13130.0% | -3764.4% | -3042.6% | -7636.0% | -1279.5% | -2293.1% | 32948.6% | -5863.2% | -1278.3% | -855.4% |
| — | -457.6% | -155.3% | -926.2% | -64.2% | -109.2% | -30.2% | -0.1% | -168.1% | +2104.2% | — | — | — | |
| Net Margin | -592.0% | -13301.2% | -7225.9% | -10292.9% | -2727.5% | 1878.3% | -5143.8% | 1192.7% | -1675.3% | 32747.6% | -8342.3% | -1349.5% | -122.8% |
| — | -808.2% | -40.5% | -963.0% | -62.8% | -94.3% | +38.3% | +188.4% | -1264.3% | +1686.3% | — | — | — |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -3.0% | -5.4% | -2.4% | -4.5% | -3.9% | 3.0% | -4.0% | 1.5% | -2.3% | 128.9% | -22.9% | -19.8% | -2.2% |
| — | -278.4% | +41.2% | -389.2% | -66.1% | -97.6% | +82.5% | +107.8% | -4.7% | +622.4% | — | — | — | |
| ROA | -2.7% | -5.2% | -2.2% | -4.3% | -3.7% | 2.8% | -3.6% | 1.4% | -2.1% | 108.7% | -14.5% | -12.9% | -1.5% |
| — | -283.1% | +37.9% | -407.1% | -76.9% | -97.4% | +75.0% | +110.8% | -42.0% | +780.1% | — | — | — | |
| ROIC | -50.4% | -6.9% | -6.3% | -6.8% | -6.9% | -5.6% | -12.0% | -15.3% | -37.2% | 926.4% | -40.2% | -51.8% | -44.6% |
| — | -22.8% | +48.0% | +55.3% | +81.5% | -100.6% | +70.1% | +70.5% | +16.4% | +1753.9% | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 19.1% YoY to 30.66x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.04 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.06 | 0.08 | 0.08 | 0.38 | 0.37 | 0.30 |
| — | +130.1% | +117.8% | -67.8% | -75.1% | -76.4% | -97.5% | -82.6% | -74.4% | -77.1% | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | 0.10 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 33.47 | 30.66 | 33.70 | 40.54 | 33.47 | 37.91 | 10.43 | 27.91 | 25.24 | 27.79 | 5.84 | 6.37 | 6.60 |
| — | -19.1% | +223.2% | +45.3% | +32.6% | +36.4% | +78.5% | +338.0% | +282.3% | +312.4% | — | — | — | |
| Quick Ratio | 33.47 | 30.66 | 33.70 | 40.54 | 33.47 | 37.91 | 10.43 | 27.75 | 25.10 | 27.77 | 5.82 | 6.35 | 6.59 |
| — | -19.1% | +223.2% | +46.1% | +33.3% | +36.5% | +79.0% | +336.7% | +280.9% | +312.1% | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | -7.63 | — | 542.93 | -23.13 | -31.02 | -27.31 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 13 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonRoivant Sciences Ltd.'s current P/E is -120.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Roivant Sciences Ltd.'s current operating margin is -3453.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Roivant Sciences Ltd.'s business trajectory between earnings reports.